Overview
Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.
Eligibility
Inclusion Criteria:
- LVEF ≤ 40%
- NYHA class II, III or ambulatory IV HF
- Receiving optimal, maximally tolerated, stable GDMT
Exclusion Criteria:
- Advanced heart failure
- Life-expectancy \< 12 months
- Evidence of right heart dysfunction


